Navigation Links
Thermo Fisher Scientific Introduces Breakthrough in RNA-Interference Technology
Date:3/10/2008

Accell siRNA Simplifies Delivery to Cells and Significantly Improves

Effectiveness of RNAi in Key Life Sciences Applications

WALTHAM, Mass., March 10 /PRNewswire-FirstCall/ -- Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, has developed a breakthrough gene-silencing tool that greatly simplifies RNA- interference (RNAi) technology and eliminates barriers associated with previous cellular delivery methods. The advance is expected to accelerate research and drug discovery in many important life sciences fields, including neuroscience, immunology, stem-cell science and oncology.

Thermo Scientific Dharmacon Accell(TM) siRNA is a novel form of short- interfering RNA (siRNA) that is absorbed directly by cells without the use of conventional delivery methods such as transfection reagents, viruses or electroporation. Dharmacon Accell siRNA effectively silences genes in all cell types tested to date.

RNAi is a powerful technology used to silence, or knock down, target genes and the proteins they produce, revealing their role in biological pathways and disease processes. Understanding gene function is critical for the development of drugs targeting those genes.

"Previous technologies for delivering siRNA into difficult cell types, such as primary cells, suspension cells, stem cells and neurons, were often ineffective and resulted in high levels of cell death," said Dr. Ian Jardine, vice president of global research and development for Thermo Fisher Scientific. "Dharmacon Accell is the only siRNA molecule that has been able to penetrate every cell type we have tested -- without the need for delivery reagents that can skew experimental results. With Dharmacon Accell siRNA and our Dharmacon SMARTvector shRNA advancement, scientists now have an effective RNAi tool set for biomedical and pharmaceutical research that will have broad implications for human health."

Dharmacon Accell siRNA is simply mixed with the optimized Accell delivery media, then added to cultured cells. It is an easy two-step process that saves researchers significant time in their laboratories and avoids the experimental variability caused by toxicity and off-target effects of conventional siRNA delivery methods.

"There is often a narrow window of conditions in which conventional siRNA delivery is effective. Dharmacon Accell siRNA achieves highly efficient siRNA delivery for gene silencing without the need for optimization," explained Jardine. "In addition, the elimination of delivery reagents, along with the associated non-specific effects, greatly simplifies the interpretation of RNAi experiments."

Preliminary studies also suggest that long-term silencing of up to 30 days can now be achieved through repeated application of Dharmacon Accell siRNA -- previously not possible with conventional synthetic siRNA reagents.

Visit http://www.thermo.com/dharmacon to purchase, or for more information on Thermo Scientific Dharmacon Accell siRNA.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, enabling our customers to make the world healthier, cleaner and safer. With annual revenues of $10 billion, we have more than 30,000 employees and serve over 350,000 customers within pharmaceutical and biotech companies, hospitals and clinical diagnostic labs, universities, research institutions and government agencies, as well as environmental and industrial process control settings. Serving customers through two premier brands, Thermo Scientific and Fisher Scientific, we help solve analytical challenges from routine testing to complex research and discovery. Thermo Scientific offers customers a complete range of high-end analytical instruments as well as laboratory equipment, software, services, consumables and reagents to enable integrated laboratory workflow solutions. Fisher Scientific provides a complete portfolio of laboratory equipment, chemicals, supplies and services used in healthcare, scientific research, safety and education. Together, we offer the most convenient purchasing options to customers and continuously advance our technologies to accelerate the pace of scientific discovery, enhance value for customers and fuel growth for shareholders and employees alike. Visit http://www.thermofisher.com.

Media Contact Information: Investor Contact Information:

Lori Gorski Ken Apicerno

Phone: 781-622-1242 Phone: 781-622-1111

E-mail: lori.gorski@thermofisher.com E-mail: ken.apicerno@thermofisher.com

Website: http://www.thermofisher.com


'/>"/>
SOURCE Thermo Fisher Scientific Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Thermo Fisher Scientific Advances Gene-Silencing Technology for Life Sciences Research
2. Life Recovery Systems Receives European CE Mark Approval for Its ThermoSuit(R) System
3. Industry Executives Finding Value in Shift of Scientific Publications
4. Childrens Mental Focus Foundation Announces a Scientific Breakthrough for Children Who Have Been Diagnosed With Autism, ADD and ADHD
5. Molecular Biometrics Hires Denny Sakkas, PhD Renowned Yale Embryologist and International Thought-Leader, as Chief Scientific Officer; Opening U.S. Research Facility
6. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
7. Second Thoughts about Fluoride, Reports Scientific American
8. XTL Biopharmaceuticals Presents Data Regarding its Hepatitis C Virus Small Molecule Program at Hep Dart 2007 - an International Scientific Conference on Viral Hepatitis
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Data Presented at the American Heart Association Scientific Sessions 2007 Demonstrated Increased HDL with ACTOS(R) (pioglitazone HCl) Slowed the Progression of Carotid Intima-Media Thickness in Patients with Type 2 Diabetes
11. New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2017)...  As the specialty pharmacy industry and the ... the revolutionary shift from volume-based to value-based care, ... patient outcomes and shaping the future of the ... from clinical trials and toward data that reveals ... therapy utilization in precise patient populations. Therigy ® ...
(Date:5/18/2017)... -- Bayer announced today that the latest research from across ... 53 rd Annual Meeting of the American Society ... Chicago . The ... and thyroid cancers, as well as lymphomas, and includes ... of copanlisib in patients with relapsed or refractory follicular ...
(Date:5/15/2017)... 2017 Enterin Inc., a privately-held CNS pharmaceutical company ... compounds to treat Parkinson,s disease (PD), has enrolled the first ... 1/2a randomized, controlled, multicenter study involving patients with PD and ... patients over a 9-to-12-month period. The first stage is open ... PD. Participating sites include Denver , ...
Breaking Medicine Technology:
(Date:5/24/2017)... ... May 24, 2017 , ... Patients who want to receive ... now meet with Dr. Joseph Bedich for a consultation, with or without a referral. ... oral health and functionality. , Dr. Bedich offers a variety of cosmetic ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. ... of the HP3 (High-Performance Periodontal Practice) continuing education (CE) series. As a compassionate ... in his field by attending numerous CE courses each year. His recent course, ...
(Date:5/24/2017)... Brentwood, TN (PRWEB) , ... May 24, 2017 ... ... announced the addition of ExtraHop to its solutions portfolio. ExtraHop delivers an analytics-first ... and security of every IT system, from the datacenter to the cloud to ...
(Date:5/24/2017)... ... 2017 , ... Rob Lowe is a sought after actor, and also serves ... the public important topics from all aspects of life, and a new segment is ... feet and ankles. , Podiatry is essential to people’s overall well-being, and if viewers ...
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Technique, technique, ... back injury when either lifting weights for strength training and exercise or simply lifting ... Center . , “Body position is everything,” Dr. Chang says. “Improper technique in lifting ...
Breaking Medicine News(10 mins):